Recent and Cumulative Cannabis Use and Sleep in Middle-Aged Adults
- 1Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
- 2Bern Institute of Primary Health Care, University of Bern, Bern, Switzerland
- 3Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts
Abstract
Importance: Cannabis is widely used and often promoted as a sleep aid, but evidence of its long-term implications for sleep is limited.
Objective: To examine the associations of cumulative cannabis exposure from young adulthood to middle age and recent cannabis use with objective and subjective sleep outcomes in middle age.
Design, Setting, and Participants: This cohort study analyzed data from the Coronary Artery Risk Development in Young Adults (CARDIA) study, including 35 years of follow-up through the year-35 examination (conducted in 2020 to 2022), and the CARDIA Year-35 Sleep Ancillary Study. Analyses were conducted from January 15 to July 15, 2026.
Exposures: Cumulative cannabis use (calculated in cannabis-years, with 1 cannabis-year equating to 365 days of use) and recent cannabis use (defined as past 30-day use vs former use and never use).
Main Outcomes and Measures: Objective sleep was assessed using data from 7-day wrist actigraphy, and subjective sleep was assessed with the Pittsburgh Sleep Quality Index (PSQI). Primary outcomes and measures were objective sleep duration (categorized as short [<6 hours], optimal [6-8 hours], or long [>8 hours]), sleep percentage (defined as percentage of time asleep; low percentage: <85%), sleep fragmentation (defined as the index of restlessness during sleep; high fragmentation: highest quartile), and wakefulness after sleep onset (WASO; prolonged WASO: ≥30 minutes) and subjective sleep quality (PSQI score and poor sleep quality: PSQI >5).
Results: A total of 1266 participants (891 with objective and 1128 with subjective sleep data) were analyzed. Among the 891 participants with objective sleep data, the mean (SD) age at the year-35 examination was 60.7 (3.6) years; the cohort included 564 females (63.3%) and 365 Black (41.0%) and 526 White (59.0%) participants. After multivariable adjustment, each additional cannabis-year was associated with higher odds of low sleep percentage (odds ratio [OR], 1.10; 95% CI, 1.06-1.14), high sleep fragmentation (OR, 1.04; 95% CI, 1.01-1.08), and prolonged WASO (OR, 1.21; 95% CI, 1.10-1.34). Compared with participants with former use and never use status, those with recent use had higher odds of low sleep percentage, high fragmentation, prolonged WASO, and long (vs optimal) sleep duration (eg, vs never use, prolonged WASO: OR, 3.23 [95% CI, 1.44-7.27]; long sleep duration: OR, 4.60 [95% CI, 1.81-11.70]). Cannabis use was not associated with subjective sleep quality.
Conclusions and Relevance: In this cohort study, both cumulative use and recent cannabis use were associated with poorer objective sleep quality, although no association with self-reported sleep quality was found. These findings underscore the importance of assessing both subjective and objective sleep and suggest potential adverse association between long-term recreational cannabis exposure and midlife sleep health.
Related
- Cumulative average lipoprotein combined index-waist circumference and incident cardiovascular disease in Chinese middle-aged and older adults
- Cumulative exposure to the remnant cholesterol inflammation index and incident diabetes mellitus in middle-aged and elderly Chinese adults : A nationwide cohort study from CHARLS
- Cumulative and Persistently Elevated Serum Uric Acid-to-HDL Cholesterol Ratio and Incident Stroke Risk Among Middle-Aged Chinese Adults: A Landmark Analysis from CHARLS
- Sleep duration, sarcopenia, and incident depressive symptoms in Chinese middle-aged and older adults : A prospective cohort study based on CHARLS
- Sleep quality moderates the association between diet and blood pressure in middle-aged and older adults: a cross-sectional study
BibTeX
@article{vu2026recent,
title = {{Recent and Cumulative Cannabis Use and Sleep in Middle-Aged Adults}},
author = {Thanh-Huyen T. Vu and Kristen L. Knutson and Reto Auer and Julian Jakob and Donald M. Lloyd-Jones and Mercedes R. Carnethon},
journal = {JAMA network open},
year = {2026},
month = oct,
doi = {10.1001/jamanetworkopen.2026.38303},
url = {https://europepmc.org/article/PMC/PMC13653285},
note = {CC BY},
}
RIS
TY - JOUR
TI - Recent and Cumulative Cannabis Use and Sleep in Middle-Aged Adults
AU - Thanh-Huyen T. Vu
AU - Kristen L. Knutson
AU - Reto Auer
AU - Julian Jakob
AU - Donald M. Lloyd-Jones
AU - Mercedes R. Carnethon
PY - 2026
DA - 2026/10/01
JO - JAMA network open
DO - 10.1001/jamanetworkopen.2026.38303
UR - https://europepmc.org/article/PMC/PMC13653285
AB - Importance: Cannabis is widely used and often promoted as a sleep aid, but evidence of its long-term implications for sleep is limited. Objective: To examine the associations of cumulative cannabis exposure from young adulthood to middle age and recent cannabis use with objective and subjective sleep outcomes in middle age. Design, Setting, and Participants: This cohort study analyzed data from the Coronary Artery Risk Development in Young Adults (CARDIA) study, including 35 years of follow-up through the year-35 examination (conducted in 2020 to 2022), and the CARDIA Year-35 Sleep Ancillary Study. Analyses were conducted from January 15 to July 15, 2026. Exposures: Cumulative cannabis use (calculated in cannabis-years, with 1 cannabis-year equating to 365 days of use) and recent cannabis use (defined as past 30-day use vs former use and never use). Main Outcomes and Measures: Objective sleep was assessed using data from 7-day wrist actigraphy, and subjective sleep was assessed with the Pittsburgh Sleep Quality Index (PSQI). Primary outcomes and measures were objective sleep duration (categorized as short [<6 hours], optimal [6-8 hours], or long [>8 hours]), sleep percentage (defined as percentage of time asleep; low percentage: <85%), sleep fragmentation (defined as the index of restlessness during sleep; high fragmentation: highest quartile), and wakefulness after sleep onset (WASO; prolonged WASO: ≥30 minutes) and subjective sleep quality (PSQI score and poor sleep quality: PSQI >5). Results: A total of 1266 participants (891 with objective and 1128 with subjective sleep data) were analyzed. Among the 891 participants with objective sleep data, the mean (SD) age at the year-35 examination was 60.7 (3.6) years; the cohort included 564 females (63.3%) and 365 Black (41.0%) and 526 White (59.0%) participants. After multivariable adjustment, each additional cannabis-year was associated with higher odds of low sleep percentage (odds ratio [OR], 1.10; 95% CI, 1.06-1.14), high sleep fragmentation (OR, 1.04; 95% CI, 1.01-1.08), and prolonged WASO (OR, 1.21; 95% CI, 1.10-1.34). Compared with participants with former use and never use status, those with recent use had higher odds of low sleep percentage, high fragmentation, prolonged WASO, and long (vs optimal) sleep duration (eg, vs never use, prolonged WASO: OR, 3.23 [95% CI, 1.44-7.27]; long sleep duration: OR, 4.60 [95% CI, 1.81-11.70]). Cannabis use was not associated with subjective sleep quality. Conclusions and Relevance: In this cohort study, both cumulative use and recent cannabis use were associated with poorer objective sleep quality, although no association with self-reported sleep quality was found. These findings underscore the importance of assessing both subjective and objective sleep and suggest potential adverse association between long-term recreational cannabis exposure and midlife sleep health.
SN - 2574-3805
ER -